<DOC>
	<DOCNO>NCT00145652</DOCNO>
	<brief_summary>This multi-center open label , randomize phase-3 study stratification accord diagnosis baseline serum-EPO level . The correction mild moderate anemia effect iron kinetics rHuEPO treatment without intravenous iron supplementation anemic patient LPD receive antineoplastic therapy study . The study perform accord ICH-GCP guideline . In order eligible , patient must consent write he/she agrees participate study . The patient recruitment period estimate long 18 month .</brief_summary>
	<brief_title>Adjuvant I.V . Iron Therapy During Erythropoetin Treatment Anemic Patients With Lymphoproliferative Disorders .</brief_title>
	<detailed_description>In multi-center , randomize , open label phase-3 study , correction mild moderate anemia effect iron kinetics rHuEPO treatment , without intravenous iron treatment , patient LPD receive antineoplastic therapy study . LENGTH OF STUDY 16 week NUMBER OF CENTERS 15 NUMBER OF SUBJECTS 66 STRATIFICATION 1 . According diagnosis ; CLL indolent NHL vs. MM . 2 . According level S-epo &gt; 100 IU/L v £ 100 IU/L baseline . TREATMENT The patient randomize receive 30 000 IU Neorecormon â ( epoetin beta ) s.c. / week 16 consecutive week +/- 100mg/week Venofer â ( iron sucrose ) week 0 6 , follow one 100mg dose every 2 week week 8 14 . If increase Hb concentration le 10g/L baseline ( week 0 ) week 4 week , dose epoetin beta increase 60 000 IU weekly week 5 . If Hb concentration exceed 140 g/L , epoetin beta therapy suspend . The treatment resume Hb concentration fall 130 g/L . This resume dose 75 % previous dose ( e.g . previous dose 30 000 IU suspension , continue dose 22 500 IU . If dose 60 000 IU suspension , dose 45 000 IU ) . If level S-ferritin reach &gt; 1000 ug/L iron sucrose suspend S-ferritin level fall 500 ug/L .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Multiple myeloma , indolent NHL CLL Anemia cancer Hb concentration within range ³ 90 £ 110 g/L measure two different occasion least two week interval inclusion within 4 week first Hb measurement . Age &gt; 18 year . Informed consent write . Demonstration stainable iron bonemarrow aspirate . Planned expect antineoplastic therapy ( except systemic low dose maintenance corticosteroid ) within 6 week follow inclusion . Cytostatic antitumor therapy ( except systemic low dose maintenance corticosteroid ) within 8 week inclusion . RBC transfusion within 8 week inclusion . RHuEPO treatment within 12 week inclusion . Any iron therapy within 4 week inclusion . Ongoing infectious disease . Active inflammatory disease malignant disease . Performance status ³ 3 accord ECOG scale . Folate deficiency ( Sfolate &lt; 4,5 nmol/L ) . B12 deficiency ( Scobalamin &lt; 145 pmol/L ) . Ongoing haemolysis define Shaptoglobin &lt; 0,2 g/L Impaired kidney function ( SCreatinine &gt; 175 mmol/L ) Acute chronic clinical relevant hepatic dysfunction ( Sbilirubin &gt; 40 umol/L ) SFerritin &gt; 800 ug/L Ongoing significant neurological psychiatric disorder include psychotic disorder dementia . Unstable uncontrolled disease relate affect cardiac function e.g. , unstable angina , congestive heart failure ( NYHA &gt; Class ) , uncontrolled hypertension ( diastolic BP &gt; 100 mmHg ) and/or uncontrolled cardiac arrhythmia . Known history allergy study medication excipients . Concurrent treatment experimental drug approve Läkemedelsverket . Male female patient reproductive potential must use approved contraceptive method ( e.g . intrauterine device ( IUD ) , birth control pill barrier device ) study 3 month study . Females childbearing potential must negative serum pregnancy test within 7 day prior study enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>erythropoetin</keyword>
	<keyword>adjuvant iron therapy</keyword>
	<keyword>anemia</keyword>
	<keyword>cancer</keyword>
</DOC>